HSSB1 regulates both the stability and the transcriptional activity of p53

Cell Research

Volumn 23, Issue 3, 2013, Pages 423-435

  Xu, Shuangbing ^a   Wu, Yuanzhong ^a   Chen, Qiong ^a   Cao, Jingying ^a   Hu, Kaishun ^a   Tang, Jianjun ^a   Sang, Yi ^a   Lai, Fenju ^a   Wang, Li ^a   Zhang, Ruhua ^a   Li, Sheng Ping ^a   Zeng, Yi Xin ^a   Yin, Yuxin ^b   Kang, Tiebang ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

acetylation; p53; stability; transcriptional activity

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; DNA BINDING PROTEIN; MITOCHONDRIAL PROTEIN; PROTEIN P53; SSBP1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL LINE; CELL STRAIN HEPG2; DNA DAMAGE; GENETIC TRANSCRIPTION; GENETICS; HUMAN; IMMUNOPRECIPITATION; METABOLISM; PHYSIOLOGY; PROTEIN BINDING; PROTEIN STABILITY; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; DNA-BINDING PROTEINS; HEP G2 CELLS; HUMANS; IMMUNOPRECIPITATION; MITOCHONDRIAL PROTEINS; PROTEIN BINDING; PROTEIN STABILITY; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84874651774     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2012.162     Document Type: Article

References (54)

1. Levine AJ, Hu W, Feng Z. The P53 pathway: what questions remain to be explored? Cell Death Differ 2006; 13:1027-1036.
2. Vousden KH, Prives C. Blinded by the light: The growing complexity of p53. Cell 2009; 137:413-431.
3. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2:594-604.
4. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9:402-412.
5. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004; 4:793-805.
6. Dai C, Gu W. p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med 2010; 16:528-536.
7. Brooks CL, Gu W. New insights into p53 activation. Cell Res 2010; 20:614-621.
8. Kruse JP, Gu W. Modes of p53 regulation. Cell 2009; 137:609-622.
9. Brooks CL, Gu W. The impact of acetylation and deacetylation on the p53 pathway. Protein Cell 2011; 2:456-462.
10. Taira N, Yoshida K. Post-translational modifications of p53 tumor suppressor: determinants of its functional targets. Histol Histopathol 2012; 27:437-443.
11. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387:296-299.
12. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387:299-303.
13. Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 2002; 4:529-533.
14. Colaluca IN, Tosoni D, Nuciforo P, et al. NUMB controls p53 tumour suppressor activity. Nature 2008; 451:76-80.
15. Kuo PC, Tsao YP, Chang HW, et al. Breast cancer amplified sequence 2, a novel negative regulator of the p53 tumor suppressor. Cancer Res 2009; 69:8877-8885.
16. Lukas J, Lukas C, Bartek J. More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance. Nat Cell Biol 2011; 13:1161-1169.
17. Drost J, Mantovani F, Tocco F, et al. BRD7 is a candidate tumour suppressor gene required for p53 function. Nat Cell Biol 2010; 12:380-389.
18. Wold MS. Replication protein A: a heterotrimeric, singlestranded DNA-binding protein required for eukaryotic DNA metabolism. Annu Rev Biochem 1997; 66:61-92.
19. Richard DJ, Bolderson E, Khanna KK. Multiple human single-stranded DNA binding proteins function in genome maintenance: structural, biochemical and functional analysis. Crit Rev Biochem Mol Biol 2009; 44:98-116.
20. Oakley GG, Patrick SM. Replication protein A: directing traffic at the intersection of replication and repair. Front Biosci 2010; 15:883-900.
21. Richard DJ, Bolderson E, Cubeddu L, et al. Single-stranded DNA-binding protein hSSB1 is critical for genomic stability. Nature 2008; 453:677-681.
22. Li Y, Bolderson E, Kumar R, et al. HSSB1 and hSSB2 form similar multiprotein complexes that participate in DNA damage response. J Biol Chem 2009; 284:23525-23531.
23. Huang J, Gong Z, Ghosal G, Chen J. SOSS complexes participate in the maintenance of genomic stability. Mol Cell 2009; 35:384-393.
24. Skaar JR, Richard DJ, Saraf A, et al. INTS3 controls the hSSB1-mediated DNA damage response. J Cell Biol 2009; 187:25-32.
25. Zhang F, Wu J, Yu X. Integrator3, a partner of single-stranded DNA-binding protein 1, participates in the DNA damage response. J Biol Chem 2009; 284:30408-30415.
26. Richard DJ, Cubeddu L, Urquhart AJ, et al. hSSB1 interacts directly with the MRN complex stimulating its recruitment to DNA double-strand breaks and its endo-nuclease activity. Nucleic Acids Res 2011; 39:3643-3651.
27. Richard DJ, Savage K, Bolderson E, et al. hSSB1 rapidly binds at the sites of DNA double-strand breaks and is required for the efficient recruitment of the MRN complex. Nucleic Acids Res 2011; 39:1692-1702.
28. Xu S, Feng Z, Zhang M, et al. hSSB1 binds and protects p21 from ubiquitin-mediated degradation and positively correlates with p21 in human hepatocellular carcinomas. Oncogene 2011; 30:2219-2229.
29. Dutta A, Ruppert JM, Aster JC, Winchester E. Inhibition of DNA replication factor RPA by p53. Nature 1993; 365:79-82.
30. Abramova NA, Russell J, Botchan M, Li R. Interaction between replication protein A and p53 is disrupted after UV damage in a DNA repair-dependent manner. Proc Natl Acad Sci USA 1997; 94:7186-7191.
31. Romanova LY, Willers H, Blagosklonny MV, Powell SN. The interaction of p53 with replication protein A mediates suppression of homologous recombination. Oncogene 2004; 23:9025-9033.
32. Bochkareva E, Kaustov L, Ayed A, et al. Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A. Proc Natl Acad Sci USA 2005; 102:15412-15417.
33. Olsson A, Manzl C, Strasser A, Villunger A. How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression? Cell Death Differ 2007; 14:1561-1575.
34. Liu L, Scolnick DM, Trievel RC, et al. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 1999; 19:1202-1209.
35. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM. Binding and modulation of p53 by p300/CBP coactivators. Nature 1997; 387:823-827.
36. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K. Recruitment of p300/CBP in p53-dependent signal pathways. Cell 1997; 89:1175-1184.
37. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997; 90:595-606.
38. Barlev NA, Liu L, Chehab NH, et al. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell 2001; 8:1243-1254.
39. Zhao Y, Lu S, Wu L, et al. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol 2006; 26:2782-2790.
40. Kitagawa M, Lee SH, McCormick F. Skp2 suppresses p53-dependent apoptosis by inhibiting p300. Mol Cell 2008; 29:217-231.
41. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253:49-53.
42. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W. Monoversus polyubiquitination: differential control of p53 fate by Mdm2. Science 2003; 302:1972-1975.
43. Rodriguez MS, Desterro JM, Lain S, Lane DP, Hay RT. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol 2000; 20:8458-8467.
44. Li M, Luo J, Brooks CL, Gu W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem 2002; 277:50607-50611.
45. Lv XB, Xie F, Hu K, et al. Damaged DNA-binding protein 1 (DDB1) interacts with Cdh1 and modulates the function of APC/CCdh1. J Biol Chem 2010; 285:18234-18240.
46. Xiao J, Zhang Z, Chen GG, et al. Nucleophosmin/B23 interacts with p21WAF1/CIP1 and contributes to its stability. Cell Cycle 2009; 8:889-895.
47. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-825.
48. Ceraline J, Deplanque G, Duclos B, et al. Inactivation of p53 in normal human cells increases G2/M arrest and sensitivity to DNA-damaging agents. Int J Cancer 1998; 75:432-438.
49. Bunz F, Dutriaux A, Lengauer C, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282:1497-1501.
50. Ando T, Kawabe T, Ohara H, Ducommun B, Itoh M, Okamoto T. Involvement of the interaction between p21 and proliferating cell nuclear antigen for the maintenance of G2/M arrest after DNA damage. J Biol Chem 2001; 276:42971-42977.
51. Lobrich M, Jeggo PA. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer 2007; 7:861-869.
52. Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 2008; 98:523-528.
53. Kang T, Wei Y, Honaker Y, et al. GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell 2008; 13:36-47.
54. Chen MS, Ryan CE, Piwnica-Worms H. Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding. Mol Cell Biol 2003; 23:7488-7497.